Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 3/20 | 0.45 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373184 | 0.87 | DHFR (0.51) | DHFR | |
| SCHEMBL4374717 | 0.86 | APP (0.48) | APPADORA1DHFR | |
| SCHEMBL4376970 | 0.86 | APP (0.47) | APPADORA2AADORA2BADORA1DHFR | |
| SCHEMBL4381814 | 0.86 | HDAC3 (0.48) | APPADORA1DHFR | |
| SCHEMBL4377864 | 0.86 | APP (0.48) | APPADORA2AADORA2BADORA1DHFR | |
| SCHEMBL4376080 | 0.85 | DHFR (0.64) | ADORA2AADORA2BADORA1ADORA3DHFR | |
| SCHEMBL4378994 | 0.84 | STAT6 (0.44) | APPADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL4377670 | 0.83 | APP (0.46) | APPADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL4378986 | 0.83 | APP (0.46) | APPADORA2AADORA2BADORA1DHFR | |
| SCHEMBL4376041 | 0.81 | APP (0.49) | APPADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1280781-A4 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2003-08-06 | — | — | EP | claimed |
| EP-1280781-A1 | 5-HT 7 RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | claimed |
| WO-2001085701-A1 | 5-HT7 RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | claimed |
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | disclosed |
| US-6630469-B2 | Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, cicadian rhythm disorders and hypertension | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-07 | — | — | US | disclosed |
| EP-1280781-A4 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-1280781-A1 | 5-HT 7 RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | disclosed |
| WO-2001085701-A1 | 5-HT7 RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032199-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | APP 2310/4885ADORA2A 37/4885ADORA2B 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.